A Study of the Effectiveness and Safety of AMG 386 and Sorafenib to Treat Advanced or Inoperable Hepatocellular Cancer

Inclusion Criteria: * Histologically confirmed advanced or inoperable HCC * Child-Pugh A liver function score * Measurable disease with at least one unidimensionally measurable lesion per RECIST 1.0 guidelines with modifications * Adequate organ and hematological function * Men or women greater than or equal to 18 years old * Eastern Cooperative Oncology Group (ECOG) performance status of 2 or less Exclusion Criteria: * Subject is eligible for a liver transplant per investigators discretion * Any previous systemic chemotherapy for HCC * History of arterial or venous thromboembolism within 12 months prior to enrollment * History of clinically significant bleeding within 6 months prior to enrollment * History of central nervous system metastases * Clinically significant cardiovascular disease within 12 months * Uncontrolled hypertension * Subjects with a history of prior malignancy